Mostrando 2 resultados de: 2
High frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusPharmacogenomic information in drug labels: European Medicines Agency perspective
ReviewAbstract: Pharmacogenomics (PGx) has a growing impact on healthcare and constitutes one of the major pillars oPalabras claves:Autores:Adrián LLerena, Caneva L., Ehmann F., Ingelman-Sundberg M., Maliepaard M., Papaluca-Amati M., Paulmichl M., Prasad K.Fuentes:scopus